When cost stops being the barrier: The new chapter of Ozempic injection in India

by | Mar 7, 2026 | Asia

Spread the love
The upcoming patent expiry for Ozempic in India is set to dramatically lower the cost of semaglutide, making this once-premium diabetes and weight-loss drug accessible to more patients. This shift could reshape the market, prompting earlier prescriptions and potentially altering societal views on weight management and body acceptance.

Written By

Written by Albert Pham, News Curator and Blogger

Related Posts

0 Comments